APO Research
Talk to an analyst

APO RESEARCH · REPORT

AAV Gene Therapy Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global AAV Gene Therapy Injection Market Outlook and Growth Opportunities 2026

26 December 2025199 pages

Choose your research edition.

Industry ResearchAAV Gene Therapy Injection Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal AAV Gene Therapy Injection Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal AAV Gene Therapy Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AAV Gene Therapy Injection Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal AAV Gene Therapy Injection Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global AAV Gene Therapy Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for AAV Gene Therapy Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for AAV Gene Therapy Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for AAV Gene Therapy Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the AAV Gene Therapy Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the AAV Gene Therapy Injection market include Avexis/Novartis (Zolgensma), BioMarin (Roctavian), CSL/uniQure (Hemgenix&Glybera), PTC Therapeutics (Upstaza), Sarepta Therapeutics (Elevidys), Spark/Roche (Luxturna), Pfizer, Suzhou NoJieBeig (Pipeline) and Belief BioMed (Pipeline), among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global AAV Gene Therapy Injection market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of AAV Gene Therapy Injection and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents AAV Gene Therapy Injection revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global AAV Gene Therapy Injection market.

AAV Gene Therapy Injection Segment by Company

Avexis/Novartis (Zolgensma)

BioMarin (Roctavian)

CSL/uniQure (Hemgenix&Glybera)

PTC Therapeutics (Upstaza)

Sarepta Therapeutics (Elevidys)

Spark/Roche (Luxturna)

Pfizer

Suzhou NoJieBeig (Pipeline)

Belief BioMed (Pipeline)

Beijing Innovikang (Pipeline)

AAV Gene Therapy Injection Segment by Type

scAAV9 Vector

AVV5 Vector

AVV2 Vector

AAVrh74 Vector

AAV Gene Therapy Injection Segment by Application

Ophthalmic Diseases

Hemophilia

Spinal Muscular Atrophy (SMA)

Duchenne Muscular Dystrophy (DMD)

Others

AAV Gene Therapy Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global AAV Gene Therapy Injection status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the AAV Gene Therapy Injection key companies, revenue, market share, and recent developments.

3. To split the AAV Gene Therapy Injection breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions AAV Gene Therapy Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify AAV Gene Therapy Injection significant trends, drivers, influence factors in global and regions.

6. To analyze AAV Gene Therapy Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AAV Gene Therapy Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AAV Gene Therapy Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AAV Gene Therapy Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global AAV Gene Therapy Injection industry.

Chapter 3: Detailed analysis of AAV Gene Therapy Injection company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of AAV Gene Therapy Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of AAV Gene Therapy Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. AAV Gene Therapy Injection Industry Trends Table 2. AAV Gene Therapy Injection Industry Drivers Table 3. AAV Gene Therapy Injection Industry Opportunities and Challenges Table 4. AAV Gene Therapy Injection Industry Restraints Table 5. Global AAV Gene Therapy Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global AAV Gene Therapy Injection Revenue Share by Company (2021-2026) Table 7. Global AAV Gene Therapy Injection Company Ranking, (2024-2026) & (US$ Million) Table 8. Global AAV Gene Therapy Injection Key Company Manufacturing Base & Headquarters Table 9. Global AAV Gene Therapy Injection Company, Product Type & Application Table 10. Global AAV Gene Therapy Injection Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global AAV Gene Therapy Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of scAAV9 Vector Table 15. Significant Companies of AVV5 Vector Table 16. Significant Companies of AVV2 Vector Table 17. Significant Companies of AAVrh74 Vector Table 18. Global AAV Gene Therapy Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global AAV Gene Therapy Injection Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global AAV Gene Therapy Injection Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global AAV Gene Therapy Injection Sales Value Share by Type (2021-2026) Table 22. Global AAV Gene Therapy Injection Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Ophthalmic Diseases Table 24. Significant Companies of Hemophilia Table 25. Significant Companies of Spinal Muscular Atrophy (SMA) Table 26. Significant Companies of Duchenne Muscular Dystrophy (DMD) Table 27. Significant Companies of Others Table 28. Global AAV Gene Therapy Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global AAV Gene Therapy Injection Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global AAV Gene Therapy Injection Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global AAV Gene Therapy Injection Sales Value Share by Application (2021-2026) Table 32. Global AAV Gene Therapy Injection Sales Value Share by Application (2027-2032) Table 33. Global AAV Gene Therapy Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global AAV Gene Therapy Injection Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global AAV Gene Therapy Injection Sales Value Share by Region (2021-2026) Table 36. Global AAV Gene Therapy Injection Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global AAV Gene Therapy Injection Sales Value Share by Region (2027-2032) Table 38. Global AAV Gene Therapy Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global AAV Gene Therapy Injection Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global AAV Gene Therapy Injection Sales Value Market Share by Country (2021-2026) Table 41. Global AAV Gene Therapy Injection Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global AAV Gene Therapy Injection Sales Value Market Share by Country (2027-2032) Table 43. Avexis/Novartis (Zolgensma) Company Information Table 44. Avexis/Novartis (Zolgensma) Business Overview Table 45. Avexis/Novartis (Zolgensma) AAV Gene Therapy Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Avexis/Novartis (Zolgensma) AAV Gene Therapy Injection Product Portfolio Table 47. Avexis/Novartis (Zolgensma) Recent Development Table 48. BioMarin (Roctavian) Company Information Table 49. BioMarin (Roctavian) Business Overview Table 50. BioMarin (Roctavian) AAV Gene Therapy Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. BioMarin (Roctavian) AAV Gene Therapy Injection Product Portfolio Table 52. BioMarin (Roctavian) Recent Development Table 53. CSL/uniQure (Hemgenix&Glybera) Company Information Table 54. CSL/uniQure (Hemgenix&Glybera) Business Overview Table 55. CSL/uniQure (Hemgenix&Glybera) AAV Gene Therapy Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. CSL/uniQure (Hemgenix&Glybera) AAV Gene Therapy Injection Product Portfolio Table 57. CSL/uniQure (Hemgenix&Glybera) Recent Development Table 58. PTC Therapeutics (Upstaza) Company Information Table 59. PTC Therapeutics (Upstaza) Business Overview Table 60. PTC Therapeutics (Upstaza) AAV Gene Therapy Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. PTC Therapeutics (Upstaza) AAV Gene Therapy Injection Product Portfolio Table 62. PTC Therapeutics (Upstaza) Recent Development Table 63. Sarepta Therapeutics (Elevidys) Company Information Table 64. Sarepta Therapeutics (Elevidys) Business Overview Table 65. Sarepta Therapeutics (Elevidys) AAV Gene Therapy Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Sarepta Therapeutics (Elevidys) AAV Gene Therapy Injection Product Portfolio Table 67. Sarepta Therapeutics (Elevidys) Recent Development Table 68. Spark/Roche (Luxturna) Company Information Table 69. Spark/Roche (Luxturna) Business Overview Table 70. Spark/Roche (Luxturna) AAV Gene Therapy Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Spark/Roche (Luxturna) AAV Gene Therapy Injection Product Portfolio Table 72. Spark/Roche (Luxturna) Recent Development Table 73. Pfizer Company Information Table 74. Pfizer Business Overview Table 75. Pfizer AAV Gene Therapy Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Pfizer AAV Gene Therapy Injection Product Portfolio Table 77. Pfizer Recent Development Table 78. Suzhou NoJieBeig (Pipeline) Company Information Table 79. Suzhou NoJieBeig (Pipeline) Business Overview Table 80. Suzhou NoJieBeig (Pipeline) AAV Gene Therapy Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Suzhou NoJieBeig (Pipeline) AAV Gene Therapy Injection Product Portfolio Table 82. Suzhou NoJieBeig (Pipeline) Recent Development Table 83. Belief BioMed (Pipeline) Company Information Table 84. Belief BioMed (Pipeline) Business Overview Table 85. Belief BioMed (Pipeline) AAV Gene Therapy Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Belief BioMed (Pipeline) AAV Gene Therapy Injection Product Portfolio Table 87. Belief BioMed (Pipeline) Recent Development Table 88. Beijing Innovikang (Pipeline) Company Information Table 89. Beijing Innovikang (Pipeline) Business Overview Table 90. Beijing Innovikang (Pipeline) AAV Gene Therapy Injection Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Beijing Innovikang (Pipeline) AAV Gene Therapy Injection Product Portfolio Table 92. Beijing Innovikang (Pipeline) Recent Development Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. AAV Gene Therapy Injection Product Image Figure 2. Global AAV Gene Therapy Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global AAV Gene Therapy Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global AAV Gene Therapy Injection Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. scAAV9 Vector Image Figure 8. AVV5 Vector Image Figure 9. AVV2 Vector Image Figure 10. AAVrh74 Vector Image Figure 11. Global AAV Gene Therapy Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global AAV Gene Therapy Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global AAV Gene Therapy Injection Sales Value Share by Type (2021-2032) Figure 14. Ophthalmic Diseases Image Figure 15. Hemophilia Image Figure 16. Spinal Muscular Atrophy (SMA) Image Figure 17. Duchenne Muscular Dystrophy (DMD) Image Figure 18. Others Image Figure 19. Global AAV Gene Therapy Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global AAV Gene Therapy Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global AAV Gene Therapy Injection Sales Value Share by Application (2021-2032) Figure 22. Global AAV Gene Therapy Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global AAV Gene Therapy Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America AAV Gene Therapy Injection Sales Value (2021-2032) & (US$ Million) Figure 25. North America AAV Gene Therapy Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe AAV Gene Therapy Injection Sales Value (2021-2032) & (US$ Million) Figure 27. Europe AAV Gene Therapy Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific AAV Gene Therapy Injection Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific AAV Gene Therapy Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America AAV Gene Therapy Injection Sales Value (2021-2032) & (US$ Million) Figure 31. South America AAV Gene Therapy Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa AAV Gene Therapy Injection Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa AAV Gene Therapy Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • scAAV9 Vector
  • AVV5 Vector
  • AVV2 Vector
  • AAVrh74 Vector
Applications
  • Ophthalmic Diseases
  • Hemophilia
  • Spinal Muscular Atrophy (SMA)
  • Duchenne Muscular Dystrophy (DMD)
  • Others
Companies covered
  • Avexis/Novartis (Zolgensma)
  • BioMarin (Roctavian)
  • CSL/uniQure (Hemgenix&Glybera)
  • PTC Therapeutics (Upstaza)
  • Sarepta Therapeutics (Elevidys)
  • Spark/Roche (Luxturna)
  • Pfizer
  • Suzhou NoJieBeig (Pipeline)
  • Belief BioMed (Pipeline)
  • Beijing Innovikang (Pipeline)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global AAV Gene Therapy Injection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global AAV Gene Therapy Injection Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 AAV Gene Therapy Injection Market Dynamics
  1. 2.1 AAV Gene Therapy Injection Industry Trends
  2. 2.2 AAV Gene Therapy Injection Industry Drivers
  3. 2.3 AAV Gene Therapy Injection Industry Opportunities and Challenges
  4. 2.4 AAV Gene Therapy Injection Industry Restraints
3 AAV Gene Therapy Injection Market by Company
  1. 3.1 Global AAV Gene Therapy Injection Company Revenue Ranking in 2025
  2. 3.2 Global AAV Gene Therapy Injection Revenue by Company (2021-2026)
  3. 3.3 Global AAV Gene Therapy Injection Company Ranking (2024-2026)
  4. 3.4 Global AAV Gene Therapy Injection Company Manufacturing Base and Headquarters
  5. 3.5 Global AAV Gene Therapy Injection Company Product Type and Application
  6. 3.6 Global AAV Gene Therapy Injection Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global AAV Gene Therapy Injection Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 AAV Gene Therapy Injection Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 AAV Gene Therapy Injection Market by Type
  1. 4.1 AAV Gene Therapy Injection Type Introduction
  2. 4.1.1 scAAV9 Vector
  3. 4.1.2 AVV5 Vector
  4. 4.1.3 AVV2 Vector
  5. 4.1.4 AAVrh74 Vector
  6. 4.2 Global AAV Gene Therapy Injection Sales Value by Type
  7. 4.2.1 Global AAV Gene Therapy Injection Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global AAV Gene Therapy Injection Sales Value by Type (2021-2032)
  9. 4.2.3 Global AAV Gene Therapy Injection Sales Value Share by Type (2021-2032)
5 AAV Gene Therapy Injection Market by Application
  1. 5.1 AAV Gene Therapy Injection Application Introduction
  2. 5.1.1 Ophthalmic Diseases
  3. 5.1.2 Hemophilia
  4. 5.1.3 Spinal Muscular Atrophy (SMA)
  5. 5.1.4 Duchenne Muscular Dystrophy (DMD)
  6. 5.1.5 Others
  7. 5.2 Global AAV Gene Therapy Injection Sales Value by Application
  8. 5.2.1 Global AAV Gene Therapy Injection Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global AAV Gene Therapy Injection Sales Value by Application (2021-2032)
  10. 5.2.3 Global AAV Gene Therapy Injection Sales Value Share by Application (2021-2032)
6 AAV Gene Therapy Injection Regional Value Analysis
  1. 6.1 Global AAV Gene Therapy Injection Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global AAV Gene Therapy Injection Sales Value by Region (2021-2032)
  3. 6.2.1 Global AAV Gene Therapy Injection Sales Value by Region: 2021-2026
  4. 6.2.2 Global AAV Gene Therapy Injection Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America AAV Gene Therapy Injection Sales Value (2021-2032)
  7. 6.3.2 North America AAV Gene Therapy Injection Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe AAV Gene Therapy Injection Sales Value (2021-2032)
  10. 6.4.2 Europe AAV Gene Therapy Injection Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific AAV Gene Therapy Injection Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific AAV Gene Therapy Injection Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America AAV Gene Therapy Injection Sales Value (2021-2032)
  16. 6.6.2 South America AAV Gene Therapy Injection Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa AAV Gene Therapy Injection Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa AAV Gene Therapy Injection Sales Value Share by Country, 2025 VS 2032
7 AAV Gene Therapy Injection Country-level Value Analysis
  1. 7.1 Global AAV Gene Therapy Injection Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global AAV Gene Therapy Injection Sales Value by Country (2021-2032)
  3. 7.2.1 Global AAV Gene Therapy Injection Sales Value by Country (2021-2026)
  4. 7.2.2 Global AAV Gene Therapy Injection Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt AAV Gene Therapy Injection Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt AAV Gene Therapy Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt AAV Gene Therapy Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Avexis/Novartis (Zolgensma)
  2. 8.1.1 Avexis/Novartis (Zolgensma) Company Information
  3. 8.1.2 Avexis/Novartis (Zolgensma) Business Overview
  4. 8.1.3 Avexis/Novartis (Zolgensma) AAV Gene Therapy Injection Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Avexis/Novartis (Zolgensma) AAV Gene Therapy Injection Product Portfolio
  6. 8.1.5 Avexis/Novartis (Zolgensma) Recent Developments
  7. 8.2 BioMarin (Roctavian)
  8. 8.2.1 BioMarin (Roctavian) Company Information
  9. 8.2.2 BioMarin (Roctavian) Business Overview
  10. 8.2.3 BioMarin (Roctavian) AAV Gene Therapy Injection Revenue and Gross Margin (2021-2026)
  11. 8.2.4 BioMarin (Roctavian) AAV Gene Therapy Injection Product Portfolio
  12. 8.2.5 BioMarin (Roctavian) Recent Developments
  13. 8.3 CSL/uniQure (Hemgenix&Glybera)
  14. 8.3.1 CSL/uniQure (Hemgenix&Glybera) Company Information
  15. 8.3.2 CSL/uniQure (Hemgenix&Glybera) Business Overview
  16. 8.3.3 CSL/uniQure (Hemgenix&Glybera) AAV Gene Therapy Injection Revenue and Gross Margin (2021-2026)
  17. 8.3.4 CSL/uniQure (Hemgenix&Glybera) AAV Gene Therapy Injection Product Portfolio
  18. 8.3.5 CSL/uniQure (Hemgenix&Glybera) Recent Developments
  19. 8.4 PTC Therapeutics (Upstaza)
  20. 8.4.1 PTC Therapeutics (Upstaza) Company Information
  21. 8.4.2 PTC Therapeutics (Upstaza) Business Overview
  22. 8.4.3 PTC Therapeutics (Upstaza) AAV Gene Therapy Injection Revenue and Gross Margin (2021-2026)
  23. 8.4.4 PTC Therapeutics (Upstaza) AAV Gene Therapy Injection Product Portfolio
  24. 8.4.5 PTC Therapeutics (Upstaza) Recent Developments
  25. 8.5 Sarepta Therapeutics (Elevidys)
  26. 8.5.1 Sarepta Therapeutics (Elevidys) Company Information
  27. 8.5.2 Sarepta Therapeutics (Elevidys) Business Overview
  28. 8.5.3 Sarepta Therapeutics (Elevidys) AAV Gene Therapy Injection Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sarepta Therapeutics (Elevidys) AAV Gene Therapy Injection Product Portfolio
  30. 8.5.5 Sarepta Therapeutics (Elevidys) Recent Developments
  31. 8.6 Spark/Roche (Luxturna)
  32. 8.6.1 Spark/Roche (Luxturna) Company Information
  33. 8.6.2 Spark/Roche (Luxturna) Business Overview
  34. 8.6.3 Spark/Roche (Luxturna) AAV Gene Therapy Injection Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Spark/Roche (Luxturna) AAV Gene Therapy Injection Product Portfolio
  36. 8.6.5 Spark/Roche (Luxturna) Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer AAV Gene Therapy Injection Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer AAV Gene Therapy Injection Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Suzhou NoJieBeig (Pipeline)
  44. 8.8.1 Suzhou NoJieBeig (Pipeline) Company Information
  45. 8.8.2 Suzhou NoJieBeig (Pipeline) Business Overview
  46. 8.8.3 Suzhou NoJieBeig (Pipeline) AAV Gene Therapy Injection Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Suzhou NoJieBeig (Pipeline) AAV Gene Therapy Injection Product Portfolio
  48. 8.8.5 Suzhou NoJieBeig (Pipeline) Recent Developments
  49. 8.9 Belief BioMed (Pipeline)
  50. 8.9.1 Belief BioMed (Pipeline) Company Information
  51. 8.9.2 Belief BioMed (Pipeline) Business Overview
  52. 8.9.3 Belief BioMed (Pipeline) AAV Gene Therapy Injection Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Belief BioMed (Pipeline) AAV Gene Therapy Injection Product Portfolio
  54. 8.9.5 Belief BioMed (Pipeline) Recent Developments
  55. 8.10 Beijing Innovikang (Pipeline)
  56. 8.10.1 Beijing Innovikang (Pipeline) Company Information
  57. 8.10.2 Beijing Innovikang (Pipeline) Business Overview
  58. 8.10.3 Beijing Innovikang (Pipeline) AAV Gene Therapy Injection Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Beijing Innovikang (Pipeline) AAV Gene Therapy Injection Product Portfolio
  60. 8.10.5 Beijing Innovikang (Pipeline) Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst